1569results about "Animal cells" patented technology

The present disclosure provides systems and methods for processing cells. The systems of the present disclosure may include a compartment, a three-dimensional (3D) matrix, a fluid flow path, an analysis unit, a preservation unit, or any combination thereof. The methods of the present disclosure may process cells via, for example, expansion, culturing, gene delivery, activation, or any combination thereof. The systems and methods described herein may be useful for producing cell products including, for example, cell therapy products.

The invention relates to a development method of an insect culture medium, which comprises the following steps: S1, constructing a double-promoter tandem vector by taking pFastBac plasmid as a skeleton; s2, establishing a baculovirus expression system; S21, transforming the double-promoter tandem vector into DH10Bac escherichia coli, so as to obtain recombinant Bacmid; s22, transfecting an Sf9 cell by using the recombinant Bacmid, so as to obtain a P0-generation baculovirus; s23, transfecting an Sf9 cell by using the P0-generation baculovirus to obtain a P1-generation baculovirus; s3, screening insect culture media: S31, providing culture media to be detected, and respectively inoculating Sf9 cells into the culture media to be detected; s32, respectively inoculating the P0-generation baculovirus or the P1-generation baculovirus into each to-be-detected culture medium for culturing; and S33, after culture is finished, detecting virus antibodies in the culture media to be detected, and screening the culture media. A comprehensive and quantitative evaluation system is established for development of the insect culture medium.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut an HLA-DRA gene, a method for modifying a CAR-T cell by using the sgRNA, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is greatly reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The invention discloses a production process for culturing nuclear polyhedrosis virus by using an S2 or SF9 cell line. The preparation method comprises the following steps: connecting a cell-penetrating peptide C105Y with DSPE-PEG2000-Mal on the surface of a lipid nanoparticle, then preparing a lipid nanoparticle LNP-C105Y by using the DSPE-PEG2000-Mal, and entrapping nuclear polyhedrosis virus DNA to obtain DNAHcNPV LNP-C105Y; the DNAHcNPV coated LNP-C105Y is inoculated into an SF9 grassland spodoptera frugiperda cell line or an S2 fruit fly cell line to be cultured, and the nuclear polyhedrosis virus is produced. On the basis of the fall webworm nuclear polyhedrosis virus, DNAHcNPV-LNP-C105Y lipid nanoparticles are synthesized and prepared by adopting a film dispersion-extrusion method to wrap the fall webworm nuclear polyhedrosis virus, and the fall webworm nuclear polyhedrosis virus is produced by inoculating the fall webworm nuclear polyhedrosis virus to SF9 and S2 cell lines. The hyphantria cunea nuclear polyhedrosis virus production process is improved, and the defect that the hyphantria cunea nuclear polyhedrosis virus production process in the prior art cannot be separated from hyphantria cunea living body feeding is overcome.

The invention relates to the technical field of medicine screening, in particular to an active substance screening platform and application thereof. The active substance screening platform comprises a cell combination; the cell combination comprises immunoregulation screening cells and antioxidant screening cells; the immunoregulation screening cell is a mouse mononuclear macrophage RAW 264.7 carrying an NF-kappa B element conserved sequence and a reporter gene; the antioxidant screening cell is a porcine small intestine epithelial cell IPEC-J2 cell carrying an ARE element conserved sequence and a reporter gene. The invention provides a screening platform based on a specific cell combination, which can quickly obtain an active substance with immune regulation, antioxidation or two functions from a large number of candidate active substances, has the advantages of low cost and high efficiency, and has important application value.

Provided is a method for biosynthesis of a human structural material type XVII collagen. The collagen comprises the amino acid sequence shown in SEQ ID NO: 2 or a variant amino acid sequence after mutation of the amino acid sequence. The variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO: 2. The collagen can promote cell adhesion and has a triple helix structure.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure relates to a protein-based article comprising a film having a thickness of about 0.1 μm to about 10 mm and comprising a crosslinked network of partially ordered polypeptides, wherein each partially ordered polypeptide independently comprises a plurality of disordered domains and a plurality of ordered domains, wherein each disordered domain independently comprises a PG or GP motif and each ordered domain independently comprises a polyalanine motif or a polyproline motif.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, anti-LILRB4 chimeric antigen receptor proteins, isolated polynucleotides encoding them, pharmaceutical compositions comprising them, and uses thereof.

The invention discloses a gene-edited tumor infiltrating lymphocyte and a T cell receptor engineered T cell and application thereof in immunotherapy. According to the invention, NR4A1 and / or NR4A2 and / or NR4A3 genes are / is knocked out from tumor infiltrating lymphocytes or T cell receptor engineered T cells, so that the multiplication capacity and the anti-tumor capacity of the tumor infiltrating lymphocytes or T cell receptor engineered T cells are improved.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The present invention provides humanized antibodies and antigen-binding fragments thereof that bind to human poliovirus (PVR), which are useful in treating tumors or cancer.

The invention relates to a nano antibody targeting CD117 and application of the nano antibody. The invention also relates to a CD117-targeting antibody or an antigen binding fragment thereof and an application of the CD117-targeting antibody or the antigen binding fragment thereof.

Disclosed herein are an engineered immune cell with CIITA gene knock-out and use thereof. According to the present invention, an sgRNA specifically targeting CIITA gene is designed and synthesized, which can accurately target CIITA gene to achieve gene knock-out with high knockout efficiency. The provided sgRNA can be used for preparing a universal CAR-T cell.

The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to TMPRSS2, and methods of using such antibodies and fragments to treat or prevent viral infection (eg, influenza virus infection). [Selected Figure] Figure 2

To provide universal antigen presenting cells.SOLUTION: Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.SELECTED DRAWING: Figure 1A

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The invention provides an anti-PD-1 antibody, a CAR-T cell, and a preparation method and application thereof. The anti-PD-1 antibody comprises LCDR-1-3 as shown in SEQ ID NO: 1-3 and HCDR-1-3 as shown in SEQ ID NO: 4-6, respectively. The CAR-T cell expresses a novel element for efficiently blocking the PD-1, and the element is a single-chain antibody for targeting the PD-1 in a cell membrane anchoring manner. And the chimeric antigen receptor and the cell membrane anchored anti-PD-1 scFv are connected by a 2A cleavage protein. The membrane anchor type anti-PD-1 scFv expressed by the CAR-T cell can almost completely block the expression of PD-1 on the surface of a T cell membrane, and further block a signal channel combined with PD-1 / PD-L1, so that the capability of T cell depletion caused by antagonism tumor of the CAR-T cell is enhanced, and the purpose of enhancing the anti-tumor effect of the CAR-T cell is achieved.

To provide a method for simply and efficiently evaluating the inducibility of a foreign matter response reaction in the skin of a test sample without using an animal, and to provide a substance having the inhibitory properties of the foreign matter response reaction in the skin and a method for searching the same.SOLUTION: The method includes a step of bringing keratinocytes transformed with a vector having an enhancer sequence containing a foreign body-responsive sequence and a sequence encoding a reporter protein downstream of the enhancer sequence into contact with a solution containing a test sample, a step of measuring the expression level of the reporter protein in the keratinocytes, and a step of evaluating the inducibility of a foreign body response reaction of the test sample in the skin based on the expression level of the reporter protein. The problem is solved by providing an agent for suppressing foreign matter response reaction in the skin containing fregula 1 found by the search method.SELECTED DRAWING: Figure 3

To provide immunotherapy that prevents or minimizes the failure of immunotherapy treatment due to the emergence of antigen-loss escape mutations in cancer cells, etc. [Solution] A bispecific chimeric antigen receptor comprising (a) an antigen-specific target-directed region containing an antigen-specific single-chain Fv(scFv) fragment that binds to at least two different antigens, (b) an extracellular spacer domain, (c) a transmembrane domain, (d) at least one costimulatory domain, and (e) an intracellular signaling domain, which is to be co-expressed with a therapeutic regulatory substance such as truncated epidermal growth factor receptor (EGFRt).

The cell-containing vessel includes a cell culture vessel, a cell culture medium contained in the cell culture vessel, a first cell layer formed on a cell culture surface of the cell culture vessel, and a second cell layer that contains stroma-forming cells and is formed on the first cell layer. The second cell layer is removable from the first cell layer.

Disclosed herein are methods, compositions, and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells, such as pluripotent embryonic stem cells. In some embodiments, the methods can include co-culturing wild-type mammalian pluripotent stem cells with modified mammalian pluripotent stem cells that include one or more genes encoding transcription factors that can drive the generation of extraembryonic or extraembryonic-like cells (e.g., GATA6, SOX17, GATA3, and / or TFAP2C genes) in a culture medium under conditions that allow the pluripotent stem cells to self-organize into post-implantation embryonic structures. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells, and the generated synthetic embryo is a human embryo.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.